These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 1759498)
1. The challenge of HIV vaccines. Girard M Vaccine; 1991 Nov; 9(11):781-3. PubMed ID: 1759498 [TBL] [Abstract][Full Text] [Related]
2. Current approaches to vaccination against human immunodeficiency viruses. Gluckman JC; Yagello M; Bahraoui E; Girard M Allergol Immunopathol (Madr); 1991; 19(1):11-3. PubMed ID: 1719790 [No Abstract] [Full Text] [Related]
3. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo. Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316 [TBL] [Abstract][Full Text] [Related]
4. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Bruck C; Thiriart C; Fabry L; Francotte M; Pala P; Van Opstal O; Culp J; Rosenberg M; De Wilde M; Heidt P; Heeney J Vaccine; 1994 Sep; 12(12):1141-8. PubMed ID: 7998425 [TBL] [Abstract][Full Text] [Related]
5. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230 [TBL] [Abstract][Full Text] [Related]
6. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Dis Markers; 1991; 9(1):51. PubMed ID: 1742945 [No Abstract] [Full Text] [Related]
7. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. Demberg T; Florese RH; Heath MJ; Larsen K; Kalisz I; Kalyanaraman VS; Lee EM; Pal R; Venzon D; Grant R; Patterson LJ; Korioth-Schmitz B; Buzby A; Dombagoda D; Montefiori DC; Letvin NL; Cafaro A; Ensoli B; Robert-Guroff M J Virol; 2007 Apr; 81(7):3414-27. PubMed ID: 17229693 [TBL] [Abstract][Full Text] [Related]
8. Are we detouring from a direct route to development of HIV vaccines? Fultz PN Vaccine; 1991 Nov; 9(11):783-7. PubMed ID: 1759499 [TBL] [Abstract][Full Text] [Related]
9. Prospects for an AIDS vaccine. Girard M Cancer Detect Prev; 1990; 14(3):411-3. PubMed ID: 2117487 [TBL] [Abstract][Full Text] [Related]
10. Modern vaccines. Human immunodeficiency virus and AIDS: challenges and progress. Schild GC; Minor PD Lancet; 1990 May; 335(8697):1081-4. PubMed ID: 1970381 [No Abstract] [Full Text] [Related]
11. Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus. Stahl-Hennig C; Voss G; Dittmer U; Coulibaly C; Petry H; Makoschey B; Cranage MP; Aubertin AM; Lüke W; Hunsmann G AIDS; 1993 Jun; 7(6):787-95. PubMed ID: 8363756 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. Lubeck MD; Natuk RJ; Chengalvala M; Chanda PK; Murthy KK; Murthy S; Mizutani S; Lee SG; Wade MS; Bhat BM AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1443-9. PubMed ID: 7888199 [TBL] [Abstract][Full Text] [Related]
13. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques. Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899 [TBL] [Abstract][Full Text] [Related]
14. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection. Pincus SH; Messer KG; Hu SL J Clin Invest; 1994 Jan; 93(1):140-6. PubMed ID: 8282780 [TBL] [Abstract][Full Text] [Related]
15. Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2. Ruby J; Brinkman C; Jones S; Ramshaw I Immunol Cell Biol; 1990 Apr; 68 ( Pt 2)():113-7. PubMed ID: 2200748 [TBL] [Abstract][Full Text] [Related]
16. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155 [TBL] [Abstract][Full Text] [Related]
17. Immunization of chimpanzees with recombinant gp160, but not infection with human immunodeficiency virus type 1, induces envelope-specific Th1 memory cells. Mannhalter JW; Fischer MB; Wolf HM; Küpcü Z; Barrett N; Dorner F; Eder G; Eibl MM J Infect Dis; 1995 Feb; 171(2):437-40. PubMed ID: 7844384 [TBL] [Abstract][Full Text] [Related]
18. Immunization of chimpanzees with the HIV-1 glycoprotein gp160 induces long-lasting T-cell memory. Mannhalter JW; Pum M; Wolf HM; Küpcü Z; Barrett N; Dorner F; Eder G; Eibl MM AIDS Res Hum Retroviruses; 1991 May; 7(5):485-93. PubMed ID: 1714748 [TBL] [Abstract][Full Text] [Related]
20. Research indicates rgp 160 provides long-term immunologic protection. Chimpanzee resists HIV challenge more than two years after vaccination. Crit Care Nurse; 1991 Sep; 11(8):1. PubMed ID: 1893756 [No Abstract] [Full Text] [Related] [Next] [New Search]